MedTech companies join AI accelerator

Three innovative Australian SMEs will use the power of data and artificial intelligence (AI) to enhance their medical products and become internationally competitive as part of a new accelerator starting this month.

Cortical Dynamics, Microbio, and Resonait Medical Technologies have been selected for the Biomedical AI Sprints Accelerator (BASA) run by leading innovation centres the Advanced Robotics for Manufacturing (ARM) Hub and MTPConnect.

These innovative companies will harness their data and AI to revolutionise their products.

At the conclusion of the accelerator, companies will have a tailored plan of how to scale their innovative AI applications and leverage data infrastructure to overcome AI adoption hurdles.

ARM Hub CEO and Founder Professor Cori Stewart said: “We are already seeing life-changing evidence of the value of AI in biomedicine with accelerated drug discovery, precision medicine, and enhanced diagnostics.”

Cortical Dynamics is a neurotechnology medical device company that has added AI to its core product, the Brain Anaesthesia Response (BARM) System and related App Cordyan, a diagnostic tool that predicts individual patient outcomes based on the anaesthetic they are given in surgery.

Zimpel said: “Enhancing our core technology with machine and deep learning applications will undoubtably result in better patient outcomes, reduce possible negative post operative complications, and positively impact on hospital costs and environmental outcomes.”

Microbio is a molecular pathogen diagnostic company commercialising InfectID-BSI, a revolutionary qPCR test to improve sepsis management by identifying 26 pathogens that cause >94% of sepsis cases directly from blood.

And Resonait is a neurotechnology company that has developed customised artificial intelligence algorithms that monitor changes in an individual’s EEG recordings that provide early indications if a patient is responding to treatment for depression.

MTPConnect CEO Stuart Dignam said: “Providing support to these promising innovative companies means we are building sovereign AI capabilities in our medical science sector and that is a smart approach if we want to be globally competitive.”

Picture: The Resonait Medical Technologies team (l-r) Gabrielle Provost, Kevin Hou, Dr Cameron Higgins (founder & CEO), and Brendan Harris.